Floatz logo

Zongertinib

Lung Cancer, Non-squamous, Non-small Cell

Boehringer IngelheimSmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

1205 Active assets in the Lung Cancer, Non-squamous, Non-small Cell cohort.

Asset / SponsorPhaseRating
Zorifertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3BBB
Necitumumab
Jonsson Comprehensive Cancer Center
Phase 3BBB
Glumetinib
Shanghai JMT-Bio Inc.
Phase 3BBB
Zoledronate
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4BBB
Icotinib
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BBB

View all 50 →

Same molecule, other indications

Zongertinib is also rated in:

breast cancerDormant
CCC
Indicative ·
55 / 100
View asset →
Solid TumoursDormant
CCC
Indicative ·
53 / 100
View asset →
Hormone Receptor Positive / HER2-negative Breast CancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →